Venus Remedies Limited (VENUSREM) Fair Value & Analysis
Healthcare · IN · Market cap ₹23.0B
Fair value as of: Jul 3, 2026
From 24 valuation models · updated today
Share price +16.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹431.30 – ₹1,947 · fair‑value band ₹1,146 – ₹1,942 · the ₹1,721 price screens above the ₹1,556 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Venus Remedies Limited (VENUSREM) currently trades at ₹1,721, while our model-based Fair Value estimate is ₹1,556 — implying the stock looks roughly 9.6% overvalued today. We read business quality at 77/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Venus Remedies Limited generated revenue of ₹7.7B at a net margin of 13.4%. Revenue grew 33.0% year over year. It earns a return on equity of 16.8%. The balance sheet holds a net cash position of ₹182M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, and solvent products, as well as herbal medicine. The company was incorporated in 1989 and is headquartered in Panchkula, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Venus Remedies Limited reported revenue of ₹7.7B in FY2026 versus ₹6.0B in FY2022, a compound +6.5%/yr. Reported net income was ₹1.0B in FY2026, compounding +26.0%/yr from FY2022.
Is VENUSREM fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,863 | ₹1,039 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Venus Remedies Limited (VENUSREM) undervalued?
What is the fair value of VENUSREM?
What is the quality score of VENUSREM?
What is the revenue of Venus Remedies Limited (VENUSREM)?
What is the net profit margin of VENUSREM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.